As of August 2026, PAHC's current EPS stands at $2.46, according to the latest financial reports. For the year 2026, the company recorded an earnings per share (EPS) of $2.46, which marks an increase compared to its EPS of $1.19 in 2025. PAHC reported an EPS of $0.54 for the quarterly report ending on Jun 30, 2026.
For 2026, Phibro Animal Health's EPS was $2.46, an increase of 106.7% from $1.19 in 2025. For the fiscal quarter that ended on Jun 30, 2026, the per-share earnings was $0.54, showing a 28.6% increase from the same quarter last year. For the twelve months ending June 2026, the EPS is $2.46. For the year 2025, the yearly earnings per share was $1.19, marking an increase of 1,883.3% from 2024.
During the last 12 months, Phibro Animal Health has seen an EPS growth of 28.6% (YoY, quarterly). Examining a broader timeline, the company maintained an average EPS growth rate of 44.8% per year for the last three years. During the last 5 years, the company had an average EPS growth rate of 12.9%. A 10-year view shows that PAHC has seen an average EPS growth of 1.5% per year.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| ZTS Zoetis Inc - Class A | 12.34 | 10.2% | 10.2% | 11.9% |
| PAHC Phibro Animal Health Corp | 14.78 | 106.7% | 44.8% | 12.9% |
| ADM Archer Daniels Midland Company | 21.67 | -39.1% | -33.9% | -6.7% |
| LLY Lilly(Eli) & Company | 39.41 | 95.6% | 49.2% | 27.5% |
| MRK Merck & Co Inc | 117.75 | 8% | 8.4% | 21.2% |
| ICCC Immucell Corp | 143.14 | 53.8% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.